• International Stem Cell shareholders authorized the sale of 100% of Lifeline Cell Technology membership interests to ATCC under a July 10, 2026 agreement.
• Transaction valued at USD 25 million in cash, subject to working capital, cash, debt adjustments; USD 2.5 million indemnity escrow, USD 100,000 adjustment escrow.
• Net cash proceeds estimated at about USD 22.1 million; intended use includes working capital, general corporate purposes.
• Closing targeted for Q3 2026; expected to occur on the second business day after closing conditions are met or waived.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Stem Cell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005767), on July 24, 2026, and is solely responsible for the information contained therein.